32nd week of 2022 patent applcation highlights part 11 |
Patent application number | Title | Published |
20220249593 | Materials and Methods for Treatment of Inflammation - The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation. | 2022-08-11 |
20220249594 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE - A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, ----, R | 2022-08-11 |
20220249595 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROME - Embodiments are directed to a method of treating acute radiation syndrome comprising administering to a subject following exposure to radiation a PIF peptide. Some embodiments describe a method of treating acute radiation syndrome following radiation exposure comprising transplanting bone marrow that has been exposed to a PIF peptide prior to transplantation into a subject. Other embodiments describe a method of increasing engraftment of a transplanted organ, tissue, or cell by pre-exposing the organ, tissue, or cell to a PIF peptide. | 2022-08-11 |
20220249596 | PIC1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY - A method of treating hypoxic ischemic encephalopathy (HIE) is described in which a classical complement pathway inhibitor is administered to a neonate. The classical pathway inhibitor can be PIC1, and may have one or more PEG moieties. Treatment of the neonate with the classical complement pathway inhibitor can inhibit inflammation and oxidative damage, such as might arise from ischemia-reperfusion injury. Improvement in fine motor performance, spatial memory and may be achieved. The method may be effective to treat or prevent cerebral palsy. | 2022-08-11 |
20220249597 | MIF INHIBITORS AND METHODS OF USE THEREOF - Provided herein are methods of treating a disease, such as Parkinson's disease, that is due to increased poly [ADP-ribose] polymerase 1 (PARP-1) activation, by inhibiting macrophage migration inhibitory factor (MIF) nuclease activity. | 2022-08-11 |
20220249599 | TREATMENT OF IMPLANTS WITH ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES - Disclosed herein are novel peptides that can comprise antimicrobial, antiviral, antifungal or antitumor activity when administered to a subject. Also disclosed herein are methods of contacting peptides to a medical device to prevent or reduce incidence of infection when the device is implanted into a subject. | 2022-08-11 |
20220249600 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif. | 2022-08-11 |
20220249601 | SPRAY DRIED FORMULATION OF A CHOLERA TOXIN B SUBUNIT VARIANT - The disclosure provides, in various embodiments, compositions, for example, powders and pharmaceutical compositions, comprising a spray-dried formulation of a cholera toxin B subunit variant and a saccharide excipient. The disclosure also provides, in various embodiments, methods of making said compositions and methods of treating a disease or enhancing wound healing using said compositions. The disclosure further provides, in various embodiments, liquid compositions comprising a cholera toxin B subunit variant and mannitol. | 2022-08-11 |
20220249602 | C-TERMINAL FRAGMENT OF TETANUS TOXIN (HC) FOR TREATMENT OF DEPRESSION - C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. | 2022-08-11 |
20220249603 | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION - This application describes compounds that are preimplantation factor (PIF) peptides, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof. This application also describes the use of those compounds for improving transplant tolerance, for restoring endocrine function, and for the treatment of transplant recipients of partial endocrine tissue grafts. | 2022-08-11 |
20220249604 | Combination Therapy for Treating Disorders of the Ear - Methods and compositions using a nucleic acid molecule encoding an atonal-associated factor in combination with a co-transcription factor and/or inhibitor of a gene silencing complex to change the sensory perception of an animal are described. | 2022-08-11 |
20220249605 | Treatment of Mood and Anxiety Disorders - The present disclosure provides compositions and formulations containing neuropeptide Y and methods of their use for the treatment of mood and anxiety disorders. | 2022-08-11 |
20220249606 | Method of treatment of degenerative diseases caused by membrane channel-forming peptides fragments - The present invention provides the method to prevent or slow down the progression of degenerative diseases caused by membrane channel-forming peptides. For many of these diseases, there is no known treatment based on the etiology and pathogenesis of the corresponding disease. Until recently, there was no integrative theory explaining multiple symptoms and observations associated with such diseases. In response to this challenge, we developed the amyloid degradation toxicity theory of Alzheimer's disease (AD). Within this concept, the etiology of the disease is the formation of beta-amyloid fragments which form membrane channels. We claim that the stopping the production of toxic fragments by inhibiting biochemical pathways producing channel-forming fragments (for example, by protease inhibitors) will prevent or slow down the progression AD. Also, we claim that the same molecular mechanism is involved in multiple neurodegenerative diseases and diabetes type II, so the invented method can be used to treat them. | 2022-08-11 |
20220249607 | Method of treatment of degenerative diseases caused by membrane channel-forming peptides fragments - The present invention provides the method to prevent or slow down the progression of degenerative diseases caused by membrane channel-forming peptides. For many of these diseases, there is no known treatment based on the etiology and pathogenesis of the corresponding disease. Until recently, there was no integrative theory explaining multiple symptoms and observations associated with such diseases. In response to this challenge, we developed the amyloid degradation toxicity theory of Alzheimer's disease (AD). Within this concept, the etiology of the disease is the formation of beta-amyloid fragments which form membrane channels. We claim that the stopping the production of toxic fragments by inhibiting biochemical pathways producing channel-forming fragments (for example, by protease inhibitors) will prevent or slow down the progression AD. Also, we claim that the same molecular mechanism is involved in multiple neurodegenerative diseases and diabetes type II, so the invented method can be used to treat them. | 2022-08-11 |
20220249608 | Method of Treating Peripheral Nerve Disorders - The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of peripheral nerve disorders. | 2022-08-11 |
20220249609 | COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES - The present invention relates, in part, to chimeric protein or chimeric protein complex comprising a CD13 targeting moiety and a signaling agent (e.g., without limitation TNF or IFN-γ) and methods of treatment using such compositions. | 2022-08-11 |
20220249610 | METHODS AND AGENTS FOR TREATING ACUTE NEUROINFLAMMATORY INJURY - This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury. | 2022-08-11 |
20220249611 | ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS AS RECEPTOR ANTAGONISTS - The present invention provides methods of screening for proteolytically stable growth factor variants, including, for example variants of human fibroblast growth factor 1 (FGF1). The present invention also provides for FGF1 variants comprising at least one amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof, wherein the resulting FGF1 variant exhibits increased proteolytic stability as compared to wild-type FGF1, as well as related uses. | 2022-08-11 |
20220249613 | CELL CULTURE FOR TREATING DISEASE IN THE LOWER LIMBS - Cell cultures for treating peripheral arterial disease, methods for producing the cell cultures and methods for treating peripheral arterial disease using the cell cultures are provided. The cell cultures may be 100 to 500 μm in size and may possess an extracellular matrix on an outer surface of the cell culture, and the like are provided. | 2022-08-11 |
20220249614 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) - The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same. | 2022-08-11 |
20220249615 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE - Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs. | 2022-08-11 |
20220249616 | Osteocrin, Lebetin or ANP for Destroying Bacterial Biofilms - The present invention relates to a natriuretic peptide selected from the group made up of (i) osteocrin, an osteocrin propeptide of osteocrin derivative, (ii) a lebetin, a lebetin fragment, or a lebetin or lebetin fragment derivative, and (iii) an ANP peptide, ANP propeptide or ANP peptide derivative, for the use thereof in a method for therapeutically treating a bacterial infection associated with a bacterial biofilm in a subject, wherein said natriuretic peptide disperses the bacterial biofilm. In a particular embodiment, the natriuretic peptide is used in combination with an antibiotic. | 2022-08-11 |
20220249617 | CYCLODEXTRIN BASED INJECTABLE COFORMULATIONS OF SGLT2 INHIBITORS AND INCRETIN PEPTIDES - Provided herein are coformulations comprising cyclodextrin that allow for concurrent, subcutaneous administration of sodium glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, and incretin peptides, such as GLP-1/Glucagon dual agonist peptides. | 2022-08-11 |
20220249618 | EXENATIDE COMPOSITIONS FOR PULMONARY ADMINISTRATION AND USE THEREOF - Provided herein are pharmaceutical compositions comprising exenatide and an aqueous buffer, wherein the pharmaceutical compositions are packaged for administration via inhalation. Methods for treating diabetes mellitus are also described. | 2022-08-11 |
20220249619 | HIGH CONCENTRATION INSULIN FORMULATION - The invention concerns a soluble insulin preparation comprising NϵB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml, Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml, Citrate in a concentration from 6 mM to 40 mM, and pH in the range from 7.0 to 8.0. The invention further comprises a method for using the soluble insulin preparation for reducing the blood glucose level in a mammal and a process for preparing the soluble insulin preparations. | 2022-08-11 |
20220249620 | COMPOSITION COMPRISING RECOMBINANT PARATHYROID HORMONE FOR HEALING AFTER ROTATOR CUFF REPAIR - The present disclosure relates to a composition for healing after rotator cuff repair, more specifically to a composition containing teriparatide as an active ingredient for healing tears of a suture site after rotator cuff repair, and the composition exhibits a tendon-to-bone healing effect when administered to patients, especially those with a tear size larger than 2 cm, for treatment of rotator cuff and is effective in lowering re-tearing rate, and thus can lead to improved healing after rotator cuff repair. | 2022-08-11 |
20220249621 | TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS - Compositions and methods are provided for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a polypeptide agent that inhibits EphB4 or EphrinB2 mediated functions. In various embodiments the methods further provide administration of a therapeutically effective amount of an immune checkpoint inhibitor. The present inventors have demonstrated that the synergistic effect of the combination of an EphB4-EphrinB2 inhibitor and checkpoint inhibitor provides superior progression-free survival (PFS) and objective response rates (ORR) patients with various cancers by activating T cell and promoting T cell and NK cell trafficking into the tumor and via migration of immune cells (e.g., CD3 and CD8) into the tumor. | 2022-08-11 |
20220249622 | METHOD FOR PROTECTING BRAIN NEURON CELLS WITH BIOACTIVE COMPOUND - A method for protecting brain neuron cells of a subject in need thereof includes administering to the subject a composition including a bioactive compound. The bioactive compound is a peptide, and comprises at least one amino acid sequences as set forth in SEQ ID NO: 1 to SEQ ID NO: 4. | 2022-08-11 |
20220249623 | VECTORS AND METHODS FOR REGENERATIVE THERAPY - An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding lysine-specific demethylase 4D (KDM4D); (b) a promoter that induces or effects overexpression of KDM4D, wherein the promoter is operably linked to the nucleic acid sequence; and (c) a regulatory element that inducibly represses the overexpression of KDM4D. The vector can be administered to a subject in a method for inducing tissue-specific hyperplasia in a mammal, including cardiomyocyte proliferation. The method provides for regenerative therapy, including improving cardiac function after myocardial infarct and other forms of cardiac damage. | 2022-08-11 |
20220249624 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS - The present disclosure relates to methods of detecting and treating inherited neuropathy. | 2022-08-11 |
20220249625 | COMPOSITIONS COMPRISING AN ENDONUCLEASE AND METHODS FOR PURIFYING AN ENDONUCLEASE - Provided are compositions comprising an endonuclease and methods for purifying an endonuclease. One aspect of the invention provides a composition comprising at least 100 mg of an untagged endonuclease having an A260/A280 absorbance ratio of from about X to about 0.8, wherein X is less than 0.8. Another aspect of the invention provides a composition, generated by contacting a composition comprising at least 100 mg of an untagged endonuclease having an A260/A280 absorbance ratio of from about X to about 0.8, wherein X is less than 0.8, with an endonuclease binding molecule, wherein the endonuclease and the endonuclease binding molecule form a protein effector. | 2022-08-11 |
20220249626 | METHODS OF AND COMPOSITIONS FOR REDUCING GENE EXPRESSION AND/OR ACTIVITY - This disclosure relates to methods of and compositions for reducing expression or activity of a variant gene comprising at least one mutation as compared its wild-type gene, comprising introducing into a cell comprising the variant gene one or more DNA sequences encoding two or more gRNAs that are complementary to two or more target sequences in the variant gene, wherein at least one of the gRNAs hybridizes to a target sequence comprising a PAM site in the variant gene that results from a mutation to the variant gene creating the PAM site that does not exist in the wild-type gene or is operably linked to a mutated portion of the wild-type gene, at least one of the gRNAs hybridizes to a target sequence comprising a PAM site in an intron of the variant gene downstream or upstream from the PAM site, and a nucleic acid sequence encoding a CRISPR-associated endonuclease; wherein a CRISPR-associated endonuclease cleaves the variant gene at the target sequences; and expression or activity of the variant gene is reduced in the cell relative to a cell in which the one or more DNA sequences encoding the two or more gRNAs and the nucleic acid sequence encoding the CRISPR-associated endonuclease are not introduced. | 2022-08-11 |
20220249627 | COMPOSITIONS AND METHODS FOR INHIBITING BIOLFILM DEPOSITION AND PRODUCTION - The invention provides a method for combating biofilm, said method comprising contacting a surface at-risk for biofilm formation or a biofilm with a composition comprising an effective amount of antimicrobial peptide biofilm-degrading enzyme combinations, preferably in the form of a fusion protein. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides a composition for use in the treatment or prevention of a biofilm infection in a subject, particularly in the oral cavity. | 2022-08-11 |
20220249628 | USE OF RECOMBINANT ADAMTS13 FOR TREATING SICKLE CELL DISEASE - The disclosure provides a method for treating sickle cell disease with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject suffering from sickle cell disease by administering ADAMTS13. The disclosure also provides a method of treating a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease by administering ADAMTS13 after the onset of the VOC. The disclosure also provides a method of preventing a VOC in a subject suffering from sickle cell disease by administering ADAMTS13 prior to the onset of the VOC. The disclosure also provides a method of determining the efficacy of a treatment for a VOC in a mouse model. | 2022-08-11 |
20220249629 | ASPARAGINASE-BASED CANCER THERAPY - The present invention relates to an improved preparation and delivery of asparaginase for use in medicine, e.g. in human and veterinary medicine. | 2022-08-11 |
20220249630 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-11 |
20220249631 | METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING - Methods and apparatuses are described for performing a patient-specific immunotherapy procedure. A computing device receives a request to create transfected T cells for a patient. The computing device generates a patient-specific identifier associated with the cell order request. The computing device initiates a process to create transfected T cells for infusion into the patient's bloodstream, comprising: performing a leukapheresis procedure on a sample of the patient's blood to collect T cells from the sample, transferring the collected T cells to a container, labeling the container with the patient-specific identifier, transmitting the collected T cells to a manufacturing facility, creating transfected T cells from the collected T cells using a cell modification technique, receiving the transfected T cells from the manufacturing facility, and infusing the transfected T cells into the patient's bloodstream. The computing device records a tracking event for each step, including the patient-specific identifier, to generate a chain of custody of the patient's T cells. | 2022-08-11 |
20220249632 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-11 |
20220249633 | PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-11 |
20220249634 | IDENTIFICATION OF IMMUNOLOGICALLY PROTECTIVE NEO-EPITOPES FOR THE TREATMENT OF CANCERS - Described herein are methods of identifying immunologically protective neo-epitopes from the cancer tissue DNA of cancer patients using biophysical principles as well as bioinformatics techniques. The identification of immunologically protective neo-epitopes provides pharmaceutical compositions with a limited number of tumor-specific peptides suitable for personalized genomics-driven immunotherapy of human cancer. Specifically disclosed herein is a method of using the conformational stability of an epitope in an MHC protein-binding groove to predict immunogenicity of peptides in a putative neo-peptide set from a tumor from a cancer patient. Pharmaceutical compositions and methods of administration are also included. | 2022-08-11 |
20220249635 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-08-11 |
20220249636 | Combination Therapy for Treating Cancer With an Antibody and Intravenous Administration of a Recombinant MVA - The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient. | 2022-08-11 |
20220249637 | COMBINATION THERAPY OF A CELL-MEDIATED CYTOTOXIC THERAPY AND AN INHIBITOR OF A PROSURVIVAL BCL2 FAMILY PROTEIN - Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of a prosurvival BCL2 family protein, e.g. a BCL2 inhibitor, for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). | 2022-08-11 |
20220249638 | HUMANIZED ANTl-CD19 ANTIBODY AND USE THEREOF WITH CHIMERIC ANTIGEN RECEPTOR - Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody. | 2022-08-11 |
20220249639 | METHODS OF TUMOR VACCINATION - Provided herein are methods for treating a tumor or generating an immune response against a tumor in a subject in need, including one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition, and one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition. The first and second composition may each comprise an allogeneic leukemia-derived cell that is useful in eliciting an immune response against the tumor. | 2022-08-11 |
20220249640 | ANTIBODIES AGAINST PD-1 AND METHODS OF USE THEREOF - The present invention is directed to human multispecific antibodies that bind to the cell-surface receptor, PD-1 (programmed death 1). The antibodies can be used to treat cancer and chronic viral infections. | 2022-08-11 |
20220249641 | INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY - The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. | 2022-08-11 |
20220249642 | Combination of Markers for Predicting the Response to Vx-001 - The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level. | 2022-08-11 |
20220249643 | ANTI-NEOPLASTIC COMBINED PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF - An anti-neoplastic combined pharmaceutical composition and application thereof. The combined pharmaceutical composition is prepared from plasmodia and chemotherapeutic drugs. The combined pharmaceutical composition combines chemotherapy with | 2022-08-11 |
20220249644 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens - The present invention relates to mutants of an | 2022-08-11 |
20220249645 | MODIFIED STRAIN OF SALMONELLA ENTERICA TYPHI - The present invention relates to the modification of a live attenuated strain of | 2022-08-11 |
20220249646 | COMPOSITION AND METHOD FOR SPRAY DRYING AN ADJUVANT VACCINE EMULSION - The invention provides for thermostable spray dried formulations including vaccines and pharmaceutical compositions for inducing or enhancing an immune response and methods of use thereof. The spray dried formulations are a dry powder generally comprising an antigen and/or an adjuvant, a metabolizable oil, and one or more excipients. | 2022-08-11 |
20220249647 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS - Therapeutic combinations of hepatitis B virus (HBV) vaccines and capsid assembly modulators are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. | 2022-08-11 |
20220249648 | RECOMBINANT BACULOVIRUS DISPLAYING AFRICAN SWINE FEVER VIRUS PROTEINS, AND AN IMMUNOLOGICAL COMPOSITION COMPRISING THE SAME - Provided are a vector, a recombinant virus, and a method of using and making thereof. Also provided are immunological compositions containing the recombinant African swine fever virus (ASFV) for inducing an immunological response in a host animal to which the immunological composition is administered. Further provided is a kit and a method of detecting the presence of ASFV immunogens in a sample from an animal. | 2022-08-11 |
20220249649 | IMMUNOGEN - Polypeptides useful in the preparation of vaccine compositions against RSV are provided. Also disclosed are methods of enhancing subdominant antibody responses in a subject. | 2022-08-11 |
20220249650 | SENECAVIRUS A VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM - The present invention is directed to novel nucleotide sequences of Senecavirus A (“SVA”), including novel genotypes thereof, which are useful as live attenuated and other vaccine compositions for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine SVA genotypes and isolates. Diagnostic and therapeutic sequences are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length SVA genomes that can replicate efficiently in host animals and tissue culture. | 2022-08-11 |
20220249651 | UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION - The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (T | 2022-08-11 |
20220249652 | INFLUENZA VIRUS NEURAMINIDASE AND USES THEREOF - In one aspect, provided herein are mutated influenza virus neuraminidase polypeptides, wherein the mutated influenza virus neuraminidase polypeptides comprise a first cytoplasmic domain, a first transmembrane domain, a first stalk domain, and a first globular head domain of a first neuraminidase of a first influenza virus with an insertion of 15 to 45 or 1 to 50 amino acid residues in the first stalk domain of the first neuraminidase. In another aspect, provided herein is an influenza virus comprising such a mutated influenza virus neuraminidase polypeptide, a genome comprising a nucleotide sequence encoding such a mutated influenza virus neuraminidase polypeptide or both. In another aspect, provided herein is an immunogenic composition comprising such an influenza virus, and optionally an adjuvant. | 2022-08-11 |
20220249653 | COMPOSITIONS AND METHODS FOR DETECTING HIV LATENCY, TREATING HIV INFECTION, AND REVERSING HIV LATENCY - Disclosed herein are compositions and uses thereof for detecting HIV latency reversal, isolating cells with HIV latency reversal, treating HIV infection, and/or reversing latency in HIV infected CD4+ T cells. In some aspects, disclosed herein is a composition and uses thereof for treating HIV infection, wherein the composition comprises one or more mature monocyte-derived dendritic cells (MDGs) having an HIV peptide bound to a Class I major histocompatibility complex (MHC) molecule and a herpesvirus peptide bound to one or more Class II MHC molecules. | 2022-08-11 |
20220249654 | NUCLEIC ACID BASED COMBINATION VACCINES - The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection. | 2022-08-11 |
20220249655 | AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS) - The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in lyophilized (freeze-dried) form, which contains a single active component, comprising the expression vector including either the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E | 2022-08-11 |
20220249656 | NANOPARTICLES FOR USE IN REDIRECTION AGAINST THE TUMOUR OF A NON-TUMOUR SPECIFIC IMMUNE RESPONSE, BASED ON A PRE-EXISTING IMMUNITY - The present patent application relates to nanoparticles for the delivery and targeting of a non-tumour-specific antigen in cancer cells, comprising a matrix support based on a biocompatible material, the non-tumour-specific antigen, and an adjuvant, for use in recalling, in cancer patients who have a specific immunity for the non-tumour-specific antigen pre-existing to the tumour pathology, the immune response specific to the non-tumour-specific antigen against the cancer cells. A further object of the application is anti-tumour pharmaceutical formulations comprising nanoparticles and kits comprising the aforementioned anti-tumour pharmaceutical formulations in combination with traditional anti-tumour vaccines. | 2022-08-11 |
20220249657 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases. | 2022-08-11 |
20220249658 | Methods Of Treatment Of Keloid Using An Anti-VEGF Agent - Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject. | 2022-08-11 |
20220249659 | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER - The present disclosure provides methods for treating or inhibiting the growth of cancer comprising selecting a patient with cancer and administering a therapeutically effective amount of a LAG-3 inhibitor in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In certain embodiments, the administration of the PD-1 inhibitor enhances the efficacy of a LAG-3 inhibitor (e.g., an anti-LAG-3 antibody or antigen-binding fragment thereof) in inhibiting the growth of cancer. | 2022-08-11 |
20220249660 | COMPOSITIONS AND METHODS FOR TREATING LUNG, COLORECTAL AND BREAST CANCER - The disclosure relates to compositions and methods for reducing the risk of developing a lung cancer, colorectal cancer, or metastatic breast cancer in a subject, and methods of treating the same, comprising identifying a subject who has one or more risk factors for lung, colorectal or metastatic breast cancer and carries IL-1 single nucleotide polymorphisms (SNPs) associated with high levels of inflammation. | 2022-08-11 |
20220249661 | Pharmaceutical composition for preventing or treating inflammatory bowel disease comprising Tumor necrosis factor alpha inhibitor and Prostaglandin E2 - The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease containing a tumor necrosis factor alpha inhibitor and prostaglandin E2 that induce regeneration or recovery of damaged intestinal mucosa. As the pharmaceutical composition for preventing or treating inflammatory bowel disease contains the tumor necrosis factor alpha inhibitor and prostaglandin E2 as active ingredients, it may be used to treat inflammatory bowel disease by improving reconstitution of damaged intestinal mucosa and the intestinal mucosal healing ability. | 2022-08-11 |
20220249662 | DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES - This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases. | 2022-08-11 |
20220249663 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION - In some aspects, the disclosure provides methods of treating cancer or an infection. In some aspects, the disclosure provides methods of enhancing the efficacy of treatment with an immune checkpoint inhibitor. In some embodiments the methods comprise administering a complement inhibitor and an immune checkpoint inhibitor to a subject with cancer or an infection. In some aspects, the disclosure provides methods of identifying a subject who is an appropriate candidate for treatment with an immune checkpoint inhibitor. In some aspects, the disclosure provides methods of identifying a subject who is an appropriate candidate for treatment with an immune checkpoint inhibitor and a complement inhibitor. In some embodiments the methods comprise determining whether the subject is an appropriate candidate for treatment with an immune checkpoint inhibitor and a complement inhibitor based on an assay of a complement system biomarker in the subject or in a sample obtained from the subject. | 2022-08-11 |
20220249664 | METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS - The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring, the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual. | 2022-08-11 |
20220249665 | TRANSFECTION METHOD - A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into cells (excluding immune cells) is provided by the present invention. Specifically, a system for delivering a target substance into a cell (excluding immune cells), including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid, a protein or a low-molecular-weight compound into a cell (excluding immune cells) by using the ultrafine bubble water, etc.; and the like are provided. | 2022-08-11 |
20220249666 | CANCER CELL-TARGETED DRUG DELIVERY CARRIER AND COMPOSITION FOR PROMOTING PHOTO-THERMAL TREATMENT EFFECTS, BOTH OF WHICH CONTAIN M1 MACROPHAGES AS ACTIVE INGREDIENT - The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of the present invention uses the M1 macrophages mobility to tumor cells and the M1 macrophage penetrability into tumors, and can deliver drugs specifically to tumor and cancer tissues only, and, when performing photo-thermal treatment by loading M1 macrophages with a photosensitive material, can significantly increase the effects, and thus is expected to be effectively used for promoting cancer treatment effects. | 2022-08-11 |
20220249667 | MICROBUBBLES - The present invention provides methods for preparing acoustically-sensitive microbubbles. The method includes the steps of: i) preparing a first surfactant solution comprising a first micelle-forming surfactant at a concentration above the critical micelle concentration (CMC); ii) adding one or more pharmaceutical compounds in a solvent to the first surfactant solution, thereby loading the micelles with the one or more pharmaceutical compounds; iii) preparing a second surfactant solution comprising a second surfactant, wherein the second surfactant comprises one or more matrix forming surfactants; iv) adding heat to the second surfactant solution to melt the surfactant and allowing the mixture to cool under rapid stirring; v) combining the second surfactant solution with the loaded micelles; vi) purging the surfactant mixture with a purging gas; vii) agitating the purged mixture under a constant stream of the purging gas; and, viii) separating the formed microbubbles by size. | 2022-08-11 |
20220249668 | DRUG TRANSDERMAL DELIVERY SYSTEM - A drug transdermal delivery system comprises sponge spicules and a low-frequency sonophoresis device, the drug transdermal delivery system firstly applies a low-frequency sonophoresis to skin using the low-frequency sonophoresis device, a surface of the skin is then massaged with the sponge spicules. | 2022-08-11 |
20220249669 | ULTRASOUND-TRIGGERED LIPOSOME PAYLOAD RELEASE - Described herein are processes and compositions for ultrasound-triggered liposome payload release, including a process for gelation and a process for enzyme catalysis. | 2022-08-11 |
20220249670 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS - The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. | 2022-08-11 |
20220249671 | CARBOHYDRATE COMPOSITION AS PHARMACEUTICAL INGREDIENT AND USE THEREOF - A carbohydrate composition includes fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of fucose is 45.5% to 76% by weight; the content of glucuronic acid is 11% to 19% by weight; the content of galactose is 4.5% to 14.5% by weight, and the content of arabinose is 5.5% to 18% by weight. A pharmaceutical ingredient including the above-mentioned carbohydrate composition is provided. | 2022-08-11 |
20220249672 | Protection and Delivery of Multiple Therapeutic Proteins - Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction. | 2022-08-11 |
20220249673 | Phosphonate-Drug Conjugates - This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided. | 2022-08-11 |
20220249674 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY - The invention relates to an endosomal and/or lysosomal escape enhancing conjugate comprising a saponin optionally linked to a targeting molecule such as an antibody and optionally linked to an effector molecule such as a toxin or an oligonucleotide. The invention also relates to a therapeutic combination of such an endosomal and/or lysosomal escape enhancing conjugate of the invention and a functionalized binding molecule comprising an effector molecule, wherein the endosomal and/or lysosomal escape enhancing conjugate comprises an enhancer of said effector molecule, i.e. a saponin. In particular the invention relates to such a therapeutic combination for use as a medicament, in particular for use in the treatment of a tumour. The invention further relates to a method of treating cancer or an autoimmune disease by administering an effective dose of the therapeutic combination to a patient in need thereof or by administering an effective dose of the endosomal and/or lysosomal escape enhancing conjugate comprising a saponin complexed with a targeting molecule such as an immunoglobulin specific for a tumor-cell surface molecule and complexed with an effector molecule, to a patient in need thereof. The invention also relates to a functionalized saponin with endosomal/lysosomal escape enhancing activity. | 2022-08-11 |
20220249675 | Composition for Preventing, Ameliorating, or Treating Gastritis or peptic Ulcer Comprising Anthocyanin-Negatively Charged Polysaccharide Complex as Active Ingredient - The present invention relates to a composition for preventing, ameliorating, or treating gastritis or peptic ulcer, comprising an anthocyanin-negatively charged polysaccharide complex as an active ingredient and, more specifically, to a composition for preventing, ameliorating, or treating gastritis or peptic ulcer, comprising an anthocyanin-negatively charged polysaccharide complex as an active ingredient, the composition exhibiting a synergistic effect as compared to anthocyanins or each of negatively charged polysaccharides. The composition comprising an anthocyanin-negatively charged polysaccharide complex as an active ingredient provided by the present invention exhibits a significantly excellent effect of relieving lesions of gastritis or peptic ulcer, and thus can be very effectively used in the development of a composition for preventing, ameliorating, or treating gastritis or peptic ulcer. | 2022-08-11 |
20220249676 | CLICK CHEMISTRY CAPTURABLE PLATINUM-BASED ANTINEOPLASTIC AGENTS - A chemotherapy agent comprising a chemotherapy group and a ligand secured to the chemotherapy group is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing chemotherapy agents from a patient is disclosed, the method comprising providing a chemotherapy agent containing a reactive group; providing a capture substrate in contact with a patient's bloodstream; administering the chemotherapy agent to the patient; and sequestering the chemotherapy agent on the capture substrate. A system for removing chemotherapy agents is also disclosed. | 2022-08-11 |
20220249677 | STARCH-BASED CARRIER MATERIAL WITH M CELL TARGETING PERFORMANCE AND PH RESPONSIVENESS, AND PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a M-cell targeting and pH-responsive starch-based carrier material, and a preparation method and application thereof. The starch-based carrier material has a molecular structure as follows, a molecular weight of 7.04×10 | 2022-08-11 |
20220249678 | PEGylated synthetic KL4 peptide, Compositions and Methods Thereof - Provided are relating to pulmonary delivery of mRNA as inhaled dry powder formulation and compositions comprising the mRNA; also provided are methods of using and making the composition. | 2022-08-11 |
20220249679 | BI-SPECIFIC BINDING AGENTS TARGETING SYNDECAN-1 AND FIBROBLAST GROWTH FACTOR RECEPTOR - Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm. | 2022-08-11 |
20220249680 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES - The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses. | 2022-08-11 |
20220249681 | DUAL DRUG ANTIBODY-DRUG CONJUGATES - Disclosed herein are dual drug antibody drug conjugates with defined stoichiometric ratios of each drug. The conjugates disclosed herein are useful for the treatment of cancer, particularly drug resistant and multidrug resistance cancer. | 2022-08-11 |
20220249682 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF - Described herein are biodegradable drug delivery conjugates and anti-cancer conjugates for effectively delivering anti-cancer agents to a subject. The conjugates include a single first cleavable peptide linker covalently connected to two polymeric segments, wherein at least one PD-L1 inhibitor is covalently bonded to each polymeric segment (referred to herein as “a PD-L1 inhibitor polymer conjugate”). Also described herein is the use of the PD-L1 inhibitor polymer conjugates in combination with anticancer agents to treat or prevent cancer. | 2022-08-11 |
20220249683 | T-CELL DEPLETING THERAPIES - Provided herein are methods of depleting T cells for therapeutic uses, including administration of anti-CD2 or anti-CD5 antibody drugs conjugates (ADCs) for treatment. Provided are anti-CD2 ADCs or anti-CD5 ADCs for use as agents to treat a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. The compositions and methods described can be used to deplete populations of CD2+ or CD5+ cells, such as CD2+ or CD5+ cancer cells or CD2+ or CD5+ immune cells, and can also be used to prepare a patient for hematopoietic stem cell transplantation or solid organ transplantation. | 2022-08-11 |
20220249684 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING IMMUNE CHECKPOINT INHIBITOR-RESISTANT CANCER - The present invention relates to a composition for preventing, ameliorating or treating immune checkpoint inhibitor-resistant cancer, comprising, as an active ingredient, a binding molecule capable of specifically binding to leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is a protein present on the surface of regulatory T cells (Treg). The binding molecule specific to the Lrig-1 protein according to the present invention suppresses the function of regulatory T cells in which the Lrig-1 protein is expressed at high levels, such as regulatory T cells in tumor infiltrating lymphocytes (TIL) or activated regulatory T cells, thereby very effectively preventing a phenomenon in which the function of effective T cells is suppresses by the regulatory T cells. Accordingly, the binding molecule specific to the Lrig-1 protein can effectively prevent, ameliorate or treat immune-evasive cancer, that is, cancer with resistance to immune checkpoint inhibitors. | 2022-08-11 |
20220249685 | ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES THEREOF - Anti-mesothelin antibodies and conjugates comprising such antibodies are disclosed herein as well as the use of such conjugates in the treatment of disease, such as cancer. | 2022-08-11 |
20220249686 | GLYCOSIDE DUAL-CLEAVAGE LINKERS FOR ANTIBODY-DRUG CONJUGATES - The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first enzymatically cleavable moiety and a second enzymatically cleavable moiety which includes a glycoside selected from a galactoside, a glucoside, a mannoside, a fucoside, O-GlcNAc, and O-GalNAc. The disclosure also encompasses compounds and methods for production of such conjugates, as well as methods of using the conjugates. | 2022-08-11 |
20220249687 | BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS - Bis(2-haloacetamido)-compounds for use as linkers to chemically cross-linking multiple thiol groups, and particularly, although not exclusively, the thiol groups of cysteine amino acids in peptide chains are described, along with their use as linking agents and resultant products which comprise antibodies, half-antibodies and antibody fragments having thiol groups bonded to said linkers (e.g. antibody-protein conjugates and antibody-drug conjugates), and methods of making said conjugates and products. (Formula I) | 2022-08-11 |
20220249688 | PLANT VIRUS PARTICLES FOR DELIVERY OF ANTIMITOTIC AGENTS - Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma. | 2022-08-11 |
20220249689 | PROTEIN-ENCLOSING POLYMERIC MICELLE - The present invention provides a polymeric complex comprising a protein and a block copolymer represented by the following formula (1). | 2022-08-11 |
20220249690 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA-LIPID NANOPARTICLE COMPLEXES ENCODING FOR VIRAL RNA POLYMERASE REGION AND PROTEIN ANTIGEN - The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. Compositions of the disclosure include RNA-lipid nanoparticle complexes encoding for viral RNA polymerase region and protein antigen. Compositions are further described where the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of 20 nm to 80 nm when measured using dynamic light scattering. The nanoemulsion compositions of the disclosure comprises a hydrophobic core, optionally including inorganic nanoparticles, in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided. | 2022-08-11 |
20220249691 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA - The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided. | 2022-08-11 |
20220249692 | Cytotoxic Particles for Targeting P2X7 Receptor - The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 receptors on a cancer cell. | 2022-08-11 |
20220249693 | NANOMATERIALS - The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use. | 2022-08-11 |
20220249694 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE - The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use. | 2022-08-11 |